Watchlist Price Alert

Exact Sciences Corporatio... (EXAS)

NASDAQ: EXAS · Real-Time Price · USD

51.52

4.36 (9.25%)

At close: May 02, 2025, 3:59 PM

51.70

0.35%

After-hours: May 02, 2025, 05:34 PM EDT

9.25% (1D)

Bid	47.5
Market Cap	9.57B
Revenue (ttm)	2.83B
Net Income (ttm)	-1.02B
EPS (ttm)	-5.53
PE Ratio (ttm)	-9.32
Forward PE	77.36
Analyst	Buy

Ask	51.95
Volume	6,087,968
Avg. Volume (20D)	2,384,848
Open	52.12
Previous Close	47.16
Day's Range	49.94 - 54.66
52-Week Range	39.97 - 72.83
Beta	0.92

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...

Sector Healthcare

IPO Date Feb 1, 2001

Employees 6,900

Stock Exchange NASDAQ

Ticker Symbol EXAS

Website https://www.exactsciences.com

Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $71, which is an increase of 37.81% from the latest price.

Stock Forecasts

Earnings Surprise

Exact Sciences has released their quartely earnings on May 1, 2025:

Revenue of $706.78M exceeds estimates by $17.43M, with 10.86% YoY growth.

EPS of -0.21 exceeds estimates by 0.16, with 65.00% YoY growth.

Why Price Moved

2 days ago

Exact Sciences shares are trading higher after the... Unlock content with Pro Subscription

1 day ago

+3.33%

Exact Sciences shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY25 sales guidance.

News

2 days ago · seekingalpha.com

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue de...

2 days ago · benzinga.com

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.

2 days ago · zacks.com

EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised

Exact Sciences ends the first quarter of 2025 on a solid note.

2 days ago · businesswire.com

Exact Sciences to Participate in May Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

3 days ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript

Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Ch...

3 days ago · zacks.com

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.50 per share a year ago.

3 days ago · businesswire.com

Exact Sciences Announces First-Quarter 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for...

4 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

1 week ago · zacks.com

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Load More News